Abstract
Introduction: FOLFIRINOX regimen is an effective therapeutic option in the treatment of advanced pancreatic cancer in patients with good PS with a significant survival benefit compared to gemcitabine. (Conroy et al., N Engl J Med 2011;364:1817). However, the toxicity profile can be relevant. In this retrospective analysis, we reviewed our experience to assess the feasibility of the regimen.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
